MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Mapping Cholinergic Signaling in Parkinson Disease Using [18F]VAT

J. O'Donnell, M. Campbell, S. Norris, B. Maiti, A. Soda, S. Moerlein, Z. Tu, J. Perlmutter (St. Louis, USA)

Meeting: 2024 International Congress

Abstract Number: 1075

Keywords: Acetylcholine, Parkinson’s, Positron emission tomography(PET)

Category: Parkinson's Disease: Neuroimaging

Objective: To determine how cholinergic signaling changes within Parkinson Disease (PD) and how these differences relate to the progression of cognitive and behavioral symptoms.

Background: Cholinergic projections in the brain play an essential role in the regulation of diverse motor and cognitive behaviors. Yet, the specific nature of how these projections change in PD remains poorly understood.  In recent work we demonstrated the utility of the [18F]VAT radiotracer to map cholinergic projections using white matter as a reference region1. Here we employ this to identify the regional distribution of cholinergic dysfunction in PD.

Method: 68 PD (40 female, 28 male, 70.8±10.6 years old) and 41 control (30 female, 11 male, 68.3±7.0 years old) underwent an [18F]VAT positron emission tomography scan. Images were reconstructed and time-activity curves were extracted using FreeSurfer5.3-based volumes of interest. Partial volume effects were corrected for using the geometric transfer matrix method. With white matter as the reference region, k2’ was estimated for each participant with cortical gray matter as the target tissue using multilinear reference tissue model (MRTM1).  k2’ (k2’ = 0.017±0.003min-1) was fixed for each participant and non-displaceable binding was estimated using MRTM22. Multiple comparisons were corrected for using the Benjamini-Hochberg method with a false discovery rate of 0.05.

Results: PD participants exhibit widespread, statistically significant differences in [18F]VAT uptake in numerous cortical and subcortical structures, including, 11% lower uptake in the thalamus, 19% in superior parietal cortex, 20% in the postcentral gyrus, and 22% in superior temporal cortex.

Conclusion: These findings suggest that a robust decrease in cholinergic signaling occurs within PD, opening the possibility for further study with cholinergic impacts on motor and cognitive symptoms using [18F]VAT.

References: 1. O’Donnell J, Soda AK, Jiang H, et al. PET Quantification of [18F]VAT in Human Brain and its Test-Retest Reproducibility and Age Dependence. J Nucl Med. 2024. Accepted. 2. Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric imaging methods: application to [11C] DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003; Vol 23: Issue 9:1096-112.

To cite this abstract in AMA style:

J. O'Donnell, M. Campbell, S. Norris, B. Maiti, A. Soda, S. Moerlein, Z. Tu, J. Perlmutter. Mapping Cholinergic Signaling in Parkinson Disease Using [18F]VAT [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/mapping-cholinergic-signaling-in-parkinson-disease-using-18fvat/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/mapping-cholinergic-signaling-in-parkinson-disease-using-18fvat/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley